From January 1, 2022 to March 31, 2022, the company has repurchased 9,156,916 shares, representing 0.83% for CNY 222.43 million. With this, the company has completed the repurchase of 21,227,523 shares, representing 1.92% for CNY 550.21 million under the buyback announced on July 26, 2021.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
29.97 CNY | -1.90% | +3.67% | -8.24% |
Apr. 23 | Salubris Pharmaceuticals' Q1 Profit Falls 5% Despite 23% Rise in Operating Income | MT |
Apr. 23 | Salubris Pharmaceuticals to Raise Capital of US Unit by $35 Million | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.24% | 4.6B | |
+18.59% | 42.77B | |
+19.78% | 22.23B | |
+13.12% | 14.44B | |
+11.79% | 13.05B | |
+35.81% | 11.59B | |
-9.08% | 6.95B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+6.29% | 4.97B |
- Stock Market
- Equities
- 002294 Stock
- News Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Tranche Update on Shenzhen Salubris Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on July 26, 2021.